Ipsen: Acromegaly trials

The registry lists 34 Acromegaly studies with Ipsen as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 1Phase 2 5Phase 3 8Phase 4 3No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With AcromegalyTerminatedNCT03045302Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedNCT02493517Phase 3Results posted
• Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyCompletedNCT02396953Phase 1/2Results posted
• Programme of Acromegaly Screening in Patients With Associated Somatic DisordersCompletedNCT02020967Results posted
• Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With AcromegalyTerminatedNCT00994214Phase 2Results posted
• Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4Results posted
• Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3Results posted
• Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3Results posted
• Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3Results posted
• A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
• Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaCompletedNCT05431803
• Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in ChinaWithdrawnNCT05184231
• Study to Predict Lanreotide-induced Disease Activity Normalization in AcromegalyWithdrawnNCT04003519
• Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic SubjectsCompletedNCT02807233
• Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mgTerminatedNCT02698384
• Validation Study of the SAGIT® Instrument in AcromegalyCompletedNCT02539927
• Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.CompletedNCT02396966
• SAGIT for Classification of Patients With Acromegaly in Clinical PracticeCompletedNCT02231593
• Predictive Factors StudyTerminatedNCT02020499
• Description of Sign-and-symptom Associations at Acromegaly Diagnosis.CompletedNCT02012127
• Somatuline Predictive Factors in Acromegaly and NETCompletedNCT01840449
• One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With MacroadenomaCompletedNCT01471405
• Study in Polish Acromegalic Patients Treated With Somatuline AutogelCompletedNCT01333384
• Non Interventional Post Marketing Programme in AcromegalyCompletedNCT00747500
• Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational StudyCompletedNCT00686348
• Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)WithdrawnNCT00517491Phase 2
• Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227
• Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
• Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
• Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2/3
• A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520
• Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
• Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
• Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4